Inotuzumab ozogamicin in B-cell acute lymphoblastic leukemias and non-Hodgkin's lymphomas.

Item

http://www.wikidata.org/entity/Q38379829

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Inotuzumab ozogamicin in B-cel ...... s and non-Hodgkin's lymphomas.

@en

type

Item

label

Inotuzumab ozogamicin in B-cel ...... s and non-Hodgkin's lymphomas.

@en

prefLabel

Inotuzumab ozogamicin in B-cel ...... s and non-Hodgkin's lymphomas.

@en

P1476

Inotuzumab ozogamicin in B-cel ...... s and non-Hodgkin's lymphomas.

@en

P2093

Daniel Guy

http://www.w3.org/2001/XMLSchema#string

Deborah Thomas

http://www.w3.org/2001/XMLSchema#string

Maro Ohanian

http://www.w3.org/2001/XMLSchema#string

P2860

CMC-544 (inotuzumab ozogamicin) shows less effect on multidrug resistant cells: analyses in cell lines and cells from patients with B-cell chronic lymphocytic leukaemia and lymphoma

Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study.

Phase I study of inotuzumab ozogamicin (CMC-544) in Japanese patients with follicular lymphoma pretreated with rituximab-based therapy.

Phase I study of anti-CD22 immunoconjugate inotuzumab ozogamicin plus rituximab in relapsed/refractory B-cell non-Hodgkin lymphoma.

Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab.

Feasibility of allografting in patients with advanced acute lymphoblastic leukemia after salvage therapy with inotuzumab ozogamicin.

Understanding and exploiting nature's chemical arsenal: the past, present and future of calicheamicin research.

Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies.

Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia: results of Cancer and Leukemia Group B Study 19802.

ITAMs versus ITIMs: striking a balance during cell regulation.

P304

601-611

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14712598.2015.1024652

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Hagop Kantarjian

Susan O'Brien

Elias Jabbour

P577

2015-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25775418

http://www.w3.org/2001/XMLSchema#string